Cargando…

Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab

BACKGROUND: Anti-tumor necrosis factor (TNF) therapies have been the mainstay of inflammatory bowel disease (IBD) treatment for nearly 2 decades. Therapies with novel mechanisms of action have been recently developed. This study compared healthcare resource utilization (HRU) and costs incurred while...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiorean, Michael, Afzali, Anita, Cross, Raymond K, Macaulay, Dendy, Griffith, Jenny, Wang, Anthony, Garcia-Horton, Viviana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802429/ https://www.ncbi.nlm.nih.gov/pubmed/36777306 http://dx.doi.org/10.1093/crocol/otaa031

Ejemplares similares

Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn’s Disease: A Retrospective Claims Database Analysis
por: Ungaro, Ryan C, et al.
Publicado: (2022)

Economic Burden of Fatigue in Inflammatory Bowel Disease
por: Ananthakrishnan, Ashwin N, et al.
Publicado: (2023)

Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease
por: Llano, Ernesto M, et al.
Publicado: (2021)

Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study
por: Hajjat, Temara M, et al.
Publicado: (2021)

CT or MR Enterography to Assess Response During Vedolizumab Therapy for Small Bowel Crohn’s Disease
por: Kwapisz, Lukasz, et al.
Publicado: (2022)

The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab
por: Harrington, Jill E, et al.
Publicado: (2020)

The Early Experience With Vedolizumab in the United States
por: Kochar, Bharati, et al.
Publicado: (2019)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review
por: Patel, Dipen, et al.
Publicado: (2022)

Impact of Cannabis Use on Inpatient Inflammatory Bowel Disease Outcomes in 2 States Legalizing Recreational Cannabis
por: Pusateri, Antoinette, et al.
Publicado: (2022)

Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system
por: Cross, Raymond K., et al.
Publicado: (2019)

Fecal Incontinence in Inflammatory Bowel Disease
por: Kamal, Natasha, et al.
Publicado: (2021)

Extraintestinal Manifestations of Inflammatory Bowel Disease Are Associated With Increased Biologic Cycling
por: Alizadeh, Madeline, et al.
Publicado: (2023)

Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling
por: Uda, Akihito, et al.
Publicado: (2020)

Vedolizumab in Mild-to-Moderate Crohn’s Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study
por: Dotti, Adriana Zanoni, et al.
Publicado: (2023)

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients
por: Breidert, Matthias, et al.
Publicado: (2020)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2020)

Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center
por: Gagnon, Ann-Lorie, et al.
Publicado: (2021)

Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib
por: Kappelman, Michael D, et al.
Publicado: (2023)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2022)

Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases
por: Singh, Siddharth, et al.
Publicado: (2022)

Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn’s Disease
por: Dulai, Parambir S, et al.
Publicado: (2022)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)
por: Alrashed, Fatema, et al.
Publicado: (2023)

Economic and Clinical Burden of Herpes Zoster Among Patients With Inflammatory Bowel Disease in the United States
por: Singer, David, et al.
Publicado: (2023)

Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
por: Remy, Clotilde, et al.
Publicado: (2022)

Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis
por: Song, Yan, et al.
Publicado: (2019)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
por: Crooks, Benjamin, et al.
Publicado: (2020)

Effect of obesity on vedolizumab response in inflammatory bowel disease
por: Levine, Louis J., et al.
Publicado: (2022)

Corticosteroids Increase the Risk of Invasive Fungal Infections More Than Tumor Necrosis Factor-Alpha Inhibitors in Patients With Inflammatory Bowel Disease
por: Gregory, Martin H, et al.
Publicado: (2023)

Natural Transmission of Helicobacter saguini Causes Multigenerational Inflammatory Bowel Disease in C57/129 IL-10(−/−) Mice
por: Mannion, Anthony, et al.
Publicado: (2020)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Loss of the Bacterial Flagellar Motor Switch Complex upon Cell Lysis
por: Kaplan, Mohammed, et al.
Publicado: (2021)

Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients
por: Pierik, Marieke J, et al.
Publicado: (2021)

Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study
por: Viola, Anna, et al.
Publicado: (2017)

L-Form Switching in Escherichia coli as a Common β-Lactam Resistance Mechanism
por: Petrovic Fabijan, Aleksandra, et al.
Publicado: (2022)

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
por: Krupka, Niklas, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6mvoi7jttho1flkacq4gm4utll